Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. (Q54577990)

1 June 2018

title

Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. (English)

1 reference

1 June 2018

1 reference

Philip Hepp

6

0 references

Klaus Friese

11

object named as

Klaus Friese

1 reference

1 June 2018

author name string

Brigitte Rack

1

1 reference

1 June 2018

Julia Jückstock

2

1 reference

1 June 2018

Maria Günthner-Biller

3

1 reference

1 June 2018

Ulrich Andergassen

4

1 reference

1 June 2018

Julia Neugebauer

5

1 reference

1 June 2018

Alexandra Schoberth

7

1 reference

1 June 2018

Doris Mayr

8

1 reference

1 June 2018

Thomas Zwingers

9

1 reference

1 June 2018

Christian Schindlbeck

10

1 reference

1 June 2018

Wolfgang Janni

12

1 reference

1 June 2018

publication date

30 June 2011

1 reference

1 June 2018

Archives of Gynecology and Obstetrics

published in

1 reference

1 June 2018

volume

285

1 reference

1 June 2018

issue

2

1 reference

1 June 2018

page(s)

485-492

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1007/s00404-011-1954-2

exact match

0 references

cites work

A pooled analysis of bone marrow micrometastasis in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Immunohistochemical profiles of brain metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

HER-2 gene amplification can be acquired as breast cancer progresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Detection and characterization of residual disease in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Combination of high-dose chemotherapy and monoclonal antibody in breast-cancer patients: a pilot trial to monitor treatment effects on disseminated tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-011-1954-2

10.1007/S00404-011-1954-2

21 January 2018

Identifiers

DOI

1 reference

1 June 2018

PubMed ID

21717141

1 reference

1 June 2018